Sotera Health Co stock (US8293551086): Q1 2026 profit rebound on 10% revenue growth

Sotera Health Co (NASDAQ: SHC) reported first?quarter 2026 results that showed a return to quarterly profitability and stronger top?line growth, beating Wall Street expectations on both earnings per share and revenue. The company posted net income of about $26.6 million, up from a net loss in the year?ago quarter, while net revenues rose 10% year over year to $280.0 million, according to a regulatory filing and earnings summary published on May 5, 2026.StockTitan as of 05/05/2026MarketBeat as of 05/05/2026

On a per?share basis, Sotera Health reported basic earnings per share from continuing operations of about $0.09 in the first quarter of 2026, compared with a basic loss per share of roughly $0.05 a year earlier, highlighting a turnaround in profitability. Adjusted EBITDA climbed to $134.7 million, reflecting improved operating performance at its Sterigenics and Nordion units, which benefited from higher volumes and pricing gains.Simply Wall St as of 05/05/2026StockTitan as of 05/05/2026

For the full year 2026, Sotera Health maintained guidance for revenue in the range of $1.2 billion to $1.3 billion, which is above the consensus revenue estimate of about $1.2 billion, and EPS guidance of $0.93 to $1.01, compared with a consensus of $0.95. The company also indicated that it expects earnings to grow roughly 11% next year, from about $0.88 to $0.98 per share, implying continued expansion if current trends hold.MarketBeat as of 05/05/2026

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

Sotera Health Co: core business model

Sotera Health Co operates as a provider of mission?critical sterilization and laboratory testing services for the medical device, pharmaceutical, and life sciences industries. The company’s Sterigenics unit offers gamma, electron beam, and ethylene oxide (EO) sterilization for medical devices and other healthcare products, while Nordion supplies medical isotopes such as cobalt?60 used in radiation therapy and sterilization. Nelson Labs provides microbiological and analytical testing services to support product safety and regulatory compliance.Sotera Health Investor Relations

This business model is highly regulated and capital intensive, with long?lived sterilization facilities and isotope production infrastructure. Sotera Health earns recurring revenue from sterilization contracts and testing services, which tend to be sticky because customers face high switching costs and strict regulatory requirements. The company’s profitability is therefore sensitive to utilization rates, pricing power, and the cost of maintaining and upgrading its facilities.StockTitan as of 05/05/2026

Main revenue and product drivers for Sotera Health Co

The first?quarter 2026 revenue growth of 10% to $280.0 million was driven by higher volumes and pricing gains at Sterigenics and Nordion. Sterigenics benefited from increased demand for sterilization services, while Nordion saw stronger sales of cobalt?60 and related isotope products, which are used both for medical treatments and for sterilizing medical devices and other healthcare items.StockTitan as of 05/05/2026

Nordion’s revenue mix can fluctuate quarter to quarter depending on harvest schedules for cobalt?60, which affects when large shipments are recognized. Nelson Labs also contributed to growth through expanded testing volumes, particularly in microbiology and analytical services for medical devices and pharmaceuticals. Together, these segments underpin Sotera Health’s narrative of reaching about $1.4 billion in revenue and roughly $280 million in earnings by 2029, assuming mid?single?digit annual revenue growth and margin expansion.Simply Wall St as of 05/05/2026

Why Sotera Health Co matters for US investors

For US investors, Sotera Health Co offers exposure to the global medical device and life sciences supply chain, which is closely tied to healthcare spending and regulatory trends in the United States. The company’s sterilization and testing services are essential for bringing medical devices and pharmaceutical products to market, giving it a structural role in the healthcare ecosystem.Sotera Health Investor Relations

SHC is listed on Nasdaq and trades in USD, making it accessible to US retail and institutional investors. Its business is also sensitive to US regulatory developments, such as FDA requirements for sterilization and testing, as well as environmental and safety rules around ethylene oxide use, which can influence operating costs and capital spending.StockTitan as of 05/05/2026

Conclusion

Sotera Health Co’s first?quarter 2026 results show a return to profitability and solid 10% revenue growth, beating analyst expectations on both EPS and sales. The company’s Sterigenics, Nordion, and Nelson Labs units all contributed to the improvement, supported by higher volumes and pricing gains.StockTitan as of 05/05/2026Simply Wall St as of 05/05/2026

At the same time, Sotera Health remains a capital?intensive business with significant long?term debt and ongoing exposure to ethylene oxide litigation and foreign?currency fluctuations, which could weigh on future cash flows and margins. For US investors, the stock offers a leveraged play on medical device and life sciences demand, but also carries regulatory, legal, and execution risks that should be carefully weighed.StockTitan as of 05/05/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.